GlassScriptPhysician profile
Jamie Groh
NPI 1497082929
$3,693.39
in general payments reported to CMS, 2019-2025
20 companies · $740 in 2025
The $740 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $70.12 · 2021: $579 · 2022: $597 · 2023: $603 · 2024: $829 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,085 · Education: $87.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,085.10 |
| Education | $87.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $941.37 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Regeneron Healthcare Solutions, INC. | $727.59 | 2019-2025 | Dupixent |
| Genzyme Corporation | $667.87 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $229.06 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $189.23 | 2023-2024 | Sotyktu |
| Janssen Biotech, INC. | $121.98 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $119.37 | 2019-2025 | Nemluvio |
| Ucb, INC. | $107.64 | 2019-2025 | Bimzelx |
| Leo Pharma INC. | $102.55 | 2021-2023 | Adbry |
| Pfizer INC. | $94.77 | 2021-2024 | |
| Amgen INC. | $71.78 | 2024-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $67.97 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $65.07 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $56.98 | 2021-2022 | |
| Smith+Nephew, INC. | $28.69 | 2020-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $27.71 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.91 | 2023 | Spevigo |
| Paratek Pharmaceuticals, INC. | $17.90 | 2024 | Nuzyra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.73 | 2019 | |
| Lilly USA, LLC | $15.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Groh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.